RetaCalc
Protocol library
SingleInvestigationalPhase 3Moderate confidenceSourced

SS-31 / Elamipretide

A mitochondria-targeting peptide with phase 3 human evidence. The best-studied schedule is indication-specific and did not meet primary efficacy endpoints in mitochondrial myopathy.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human Study
Adults with genetically confirmed primary mitochondrial myopathy

40 mg subcutaneously once daily for 24 weeks

MMPOWER-3 was a monitored phase 3 trial and did not improve its primary walking-distance or fatigue endpoints.

View source
Human Study
Adults with primary mitochondrial myopathy

40 mg subcutaneously once daily for four weeks in a crossover study

This small phase 2 study generated signals that were not confirmed on the phase 3 primary endpoints.

View source

Evidence summary

A mitochondria-targeting peptide with phase 3 human evidence. The best-studied schedule is indication-specific and did not meet primary efficacy endpoints in mitochondrial myopathy.

Protocol basis

The protocol is anchored to matched elamipretide formulation and disease-specific controlled trials. It is one of the stronger investigational evidence sets in the library.

What remains uncertain

Generalisability outside mitochondrial disease, long-term clinical benefit and equivalence to products labelled only SS-31 remain unresolved.

Warnings and contraindications

Elamipretide remains indication- and formulation-specific research.
Injection-site reactions were common in the phase 3 mitochondrial myopathy trial.
A trial schedule is not evidence for general wellness or performance use.